Home › Entities › clinical_trial › Second Open Label Extension to Bridging Study CTBM100C2303

Second Open Label Extension to Bridging Study CTBM100C2303

clinical trial
MedicalStudy clinical_trial Q61938896
Press Enter · cited answer in seconds

Summary

Second Open Label Extension to Bridging Study CTBM100C2303 is a clinical trial[1].

Key Facts

  • Second Open Label Extension to Bridging Study CTBM100C2303 is in the country of Bulgaria[2].
  • Second Open Label Extension to Bridging Study CTBM100C2303 is in the country of Estonia[3].
  • Second Open Label Extension to Bridging Study CTBM100C2303 is in the country of Latvia[4].
  • Second Open Label Extension to Bridging Study CTBM100C2303 is in the country of Lithuania[5].
  • Second Open Label Extension to Bridging Study CTBM100C2303 is in the country of Romania[6].
  • Second Open Label Extension to Bridging Study CTBM100C2303 is in the country of South Africa[7].
  • Second Open Label Extension to Bridging Study CTBM100C2303's instance of is recorded as clinical trial[8].
  • Second Open Label Extension to Bridging Study CTBM100C2303's start time is recorded as +2010-02-28T00:00:00Z[9].
  • Second Open Label Extension to Bridging Study CTBM100C2303's end time is recorded as +2012-04-30T00:00:00Z[10].
  • Second Open Label Extension to Bridging Study CTBM100C2303's sponsor is recorded as Novartis[11].
  • Second Open Label Extension to Bridging Study CTBM100C2303's main subject is recorded as cystic fibrosis[12].
  • Second Open Label Extension to Bridging Study CTBM100C2303's number of participants is recorded as {'unit': '1', 'amount': '+49'}[13].
  • Second Open Label Extension to Bridging Study CTBM100C2303's title is recorded as A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Completed Participation in Study CTBM100C2303E1.[14].
  • Second Open Label Extension to Bridging Study CTBM100C2303's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+6'}[15].
  • Second Open Label Extension to Bridging Study CTBM100C2303's ClinicalTrials.gov ID is recorded as NCT01069705[16].
  • Second Open Label Extension to Bridging Study CTBM100C2303's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+21'}[17].
  • Second Open Label Extension to Bridging Study CTBM100C2303's research intervention is recorded as tobramycin[18].
  • Second Open Label Extension to Bridging Study CTBM100C2303's clinical trial phase is recorded as phase III clinical trial[19].
  • Second Open Label Extension to Bridging Study CTBM100C2303's research site is recorded as Novartis[20].
  • Second Open Label Extension to Bridging Study CTBM100C2303's research subject recruitment status is recorded as completed[21].
  • Second Open Label Extension to Bridging Study CTBM100C2303's study type is recorded as interventional study[22].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . wikidata.org.
  17. [18] ↑ . wikidata.org.
  18. [19] ↑ . wikidata.org.
  19. [20] ↑ . wikidata.org.
  20. [21] ↑ . wikidata.org.
  21. [22] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Second Open Label Extension to Bridging Study CTBM100C2303. Retrieved May 3, 2026, from https://4ort.xyz/entity/second-open-label-extension-to-bridging-study-ctbm100c2303
MLA “Second Open Label Extension to Bridging Study CTBM100C2303.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/second-open-label-extension-to-bridging-study-ctbm100c2303.
BibTeX @misc{4ortxyz_second-open-label-extension-to-bridging-study-ctbm100c2303_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Second Open Label Extension to Bridging Study CTBM100C2303}}, year = {2026}, url = {https://4ort.xyz/entity/second-open-label-extension-to-bridging-study-ctbm100c2303}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Second Open Label Extension to Bridging Study CTBM100C2303 — https://4ort.xyz/entity/second-open-label-extension-to-bridging-study-ctbm100c2303 (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/second-open-label-extension-to-bridging-study-ctbm100c2303 · Last refreshed: